Analysis Calmare Therapeutics Inc. (CTTC)
5/31/2024
Analysis of Calmare Therapeutics Inc. (CTTC)
Calmare Therapeutics Inc. (CTTC) has shown a consistent price of 0.0001 for several months, with occasional spikes such as on April 20th, 2023, when the price briefly rose to 0.0245. However, since then, the price has returned to its previous levels.Technical indicators such as RSI, MACD, and moving averages are not available for analysis due to missing data. It appears that CTTC is a low-priced stock with limited volatility based on the available data.
Further analysis would require additional information and a more comprehensive dataset to assess the stock's potential for future price movements.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous results, ending on February 27, 2025, were handled by the Transfer Agent. The results from January 31, 2025, were released after hours. The results from October 31, 2024, were not provided at the time. The results from August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuations metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has a strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and key financial figures include EBITDA, revenue, diluted EPS, gross profit, and net income.
Moving on to stock statistics, the company has a short ratio, float shares, shares short, and average trading volumes. The percentage held by insiders and institutions, as well as the short percent of shares outstanding, are also provided.
Valuations metrics show the company's PEG ratio, forward and trailing P/E ratios, enterprise value, price to book ratio, price to sales ratio, and multiples of enterprise value to EBITDA and revenue. The market capitalization is also included.
The stock price summary presents information on beta, moving averages, fifty-two-week low and high prices, and the change in the stock price over the past year.
Lastly, dividends and splits data include the payout ratio, dividend dates, split dates, dividend rates, and yields. The company's dividend history and average yield over five years are also mentioned.
Income statement 💸
Here are the revenue figures for the past four fiscal years:1. Fiscal Year 2023: Sales of $383,285,000,000
2. Fiscal Year 2022: Sales of $394,328,000,000
3. Fiscal Year 2021: Sales of $365,817,000,000
4. Fiscal Year 2020: Sales of $274,515,000,000
From these figures, we can observe the following trends:
- There was a decrease in sales from FY 2022 to FY 2023.
- Prior to FY 2023, there was a general increasing trend in sales over the years.
- The highest sales figure was recorded in FY 2022.
These trends can provide insights into the company's performance and market conditions over the specified period.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has been relatively stable over the years, indicating consistent operational performance.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. Financing activities show significant fluctuations, especially in common stock repurchases and long-term debt issuances.
5. Investing activities also vary, with notable amounts spent on the sale and purchase of investments.
6. The end cash position has been fluctuating, reaching its highest value in 2020 and its lowest in 2022.
These conclusions provide insights into the company's financial performance and management of cash flows over the years.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.33, compared to $1.26 a year ago. The range of estimates is between $1.27 and $1.36, with 26 analysts providing forecasts.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.53, lower than the $1.46 EPS reported a year ago. The estimates range from $1.44 to $1.63, with 25 analysts contributing to the forecasts.
3. For the current fiscal year ending on September 30, 2024, the average estimated EPS is $6.59, up from $6.13 in the previous year. The EPS estimates range from $6.43 to $6.92, with 39 analysts providing their projections.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average estimated EPS is $7.23, compared to $6.59 in the previous year. The EPS estimates for the upcoming year range from $6.40 to $7.90, with 39 analysts involved in the forecasting process.
Overall, it appears that analysts are generally optimistic about the company's future earnings per share, with expected growth in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates indicate a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions about the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated growth rate for the next 5 years is 11%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the next 5 years compared to the past 5 years. The company is projected to experience steady growth in the short term, with a higher growth rate expected in the next year compared to the current year.
Price target
Based on the analysts' forecast, the future price of the security is expected to range between $164 (low) and $250 (high), with a median estimate of $200 and an average estimate of $202.26. The current price of the security is $191.57.Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has shown an increasing trend, with the highest value in 2018 at $107,147,000,000.
6. The company has been relying more on non-current assets to support its operations.
7. There has been a consistent increase in shareholders' equity, indicating a positive trend in the company's financial health.
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
